Results 181 to 190 of about 23,011 (205)

EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*

Blood, 2011
Emilio Berti, , Reinhard Dummer
exaly  

Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer

Biomaterials, 2013
Nianxi Zhao, Youli Zu, Parag Parekh
exaly  

CD30

2011
openaire   +1 more source

CD30: expression and function in health and disease

Seminars in Immunology, 1998
Toshiki Watanabe, Ryouichi HORIE
exaly  

CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis

Histopathology, 2013
Tracy I George, Manuela Mollejo, Alberto Zamo   +2 more
exaly  

ANTI-CD30 ANTIBODIES THAT BIND TO INTACT CD30 BUT NOT SOLUBLE CD30

2007
PASTAN IRA H, NAGATA SATOSHI, ONDA MASANORI, ISE TOMOKO, RAUBITSCHEK ANDREW   +4 more
openaire   +1 more source

High serum level of soluble CD30 in acute primary HIV-1 infection

Clinical and Experimental Immunology, 2003
Fabrizio Vinante, Marco Chilosi, G Nadali   +2 more
exaly  

Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin–Reed-Sternberg cells

Oncogene, 2002
Toshiki Watanabe, Ryouichi HORIE, Masaaki Higashihara   +2 more
exaly  

CD30 bispecific antibodies and method of immunotherapy of CD30+ malignancies

2023
MEDIN JEFFREY A, LUM LAWRENCE G, OLDHAM ROBYN A A, THAKUR ARCHANA   +3 more
openaire   +1 more source

Loss of CD30 expression in metastatic embryonal carcinoma: the effects of chemotherapy?

Histopathology, 2001
R T Oliver
exaly